Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Lakshmi Bhagat, Daqing Wang, Weiwen Jiang, and Sudhir Agrawal | ||||||||||||
Title | Abstract 2570: IMO-8400, a selective antagonist of TLRs 7, 8 and 9, inhibits MYD88 L265P mutation-driven signaling and cell survival: A potential novel approach for treatment of B-cell lymphomas harboring MYD88 L265P mutation | ||||||||||||
|
|||||||||||||
URL | http://cancerres.aacrjournals.org/content/74/19_Supplement/2570.short | ||||||||||||
Abstract Text | Cancer Res October 1, 2014 74:2570 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bazlitoran | Bazlitoran | 0 | 2 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Bazlitoran | IMO-8400 | Bazlitoran (IMO-8400) is a TLR 7, 8 and 9 antagonist, which leads to decreased growth of tumors with activated TLR signaling (Cancer Res October 1, 2014 74:2570, PMID: 27876460). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|